Insights
Insights From Our Experts
Articles
PharmaVOICE Digital Influencers: Brigham Hyde
Data Is Transforming the Landscape In a special feature on Digital Influencers, PharmaVOICE Editor Taren Grom sat down with Brigham Hyde, President, Data & Analytics to discuss how data is transforming the life sciences landscape as…
How to Enhance Provider and Patient Engagement in Tech-Savvy Healthcare
Pharmaceutical representatives have always been a welcomed resource and consistent office visitor for healthcare providers (HCPs). Today, in a world operating largely virtually, pharma reps are re-strategizing HCP engagement in the same way providers are rethinking…
High-Efficiency Commercialization for High-Science Brands
Posted by
Chien Sun, PhD on January 6, 20211/6/21
High-stake or complex therapies, such as cell and gene therapies, immunotherapies and RNA interference (RNAi), have the potential to change the course of treatment for cancer patients and patients with rare diseases. But first, pharma companies must work with providers to navigate patient access complications…
Leading the Way in Digital Health With Tech-Driven Clinical Pathways
Digital health technologies have become integral to patient care since the beginning of the COVID-19 pandemic and will remain essential healthcare tools. As many patients and healthcare providers are embracing digital health devices, clinical pathway developers have…
Patient Empowerment on the Rise with Health Consumerism
There’s no question that the pharma industry is evolving, and so are company relationships with patients as health consumerism gains popularity. While the COVID-19 pandemic created an immediate need for telehealth options, patients are seeing their own personal needs for customized healthcare options overall. Today’s…
How Does the Biden Administration Want to ‘Take on Pharma?’
Throughout his campaign, Biden has promised to, once in office, expand access to health care through the “Biden Plan,” an evolution of former President Barack Obama’s Affordable Care Act, dubbed “Obamacare,” while “taking on big pharma”…
Achieve Price and Access Launch Excellence in a Disrupted World
With the U.S. election behind us, the soaring costs of U.S. healthcare have become a priority for politicians—in particular, the cost of prescription drugs. Some proposed solutions involve external reference pricing from comparable countries and limiting drug price increases. These anticipated changes in U.S. pricing policy, coupled with the downward pressure on…
Insights From Dreamforce 2020 Panel: End-To-End Patient Engagement
EVERSANA was proud to participate in this year’s brand-new session “End-To-End Patient Engagement: From Clinical Trials Through Patient Support Programs.“ Bhaskar Sambasivan, Chief Strategy Officer and President of Patient Services, provided valuable insight into the emerging…
Insights From Trade & Channel Strategies Conference 2020
Now more than ever, pharma manufacturers need to break the cycle of supply chain complexity to better connect patients to therapy. On Tuesday, December 1, EVERSANA’s Scot Buchanan moderated the panel “Emerging and Future Trends in Channel…
DSCSA Guidelines – Best Practices for Compliance and Supply Chain Integration
On November 27, 2023, all drug manufacturers must participate in an electronic package-level traceability system, commonly known as the “interoperability” requirement. EVERSANA is equipped to help manufacturers navigate these new guidelines and apply best practices. Let’s…